Hello, my name's Corey Langer. I'm Professor of Medicine at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia. It's my privilege to discuss some of the new findings in ALK positive non small cell lung cancer. Specifically, I will focus on the important implications of the J ALEX trial, potential implications of the ALTA trial looking at brigatinib, and then newer agents in this class, including lorlatinib.
The J ALEX trial is a critical Phase III effort in ALK inhibitor naive ALK positive non small cell, comparing the standard of practice crizotinib to a new, third generation ALK inhibitor specific for ALK and ROS 1 called alectinib.
